Fibromyalgia and Psychological Trauma: What Pain Physiology Shows

Fibromyalgia is often described as “pain without a cause”, yet studies indicate failure of descending pain inhibition and signs of central sensitisation. This helps explain why standard analgesics perform poorly, and why psychological trauma and stress-related disorders can amplify symptoms via stress–immune–pain axes.

A new window on pain mechanisms: tests of descending inhibition

In clinical fibromyalgia, pain is widespread and persistent, while classical inflammatory “foci” are not seen. A key hypothesis is dysfunction of the system that normally dampens nociceptive input. It can be probed with conditioned pain modulation (CPM) paradigms, where one painful stimulus should reduce perception of another. In a cross-sectional study of 103 women with fibromyalgia, two CPM variants were compared: a 12 °C cold-pressor “hand” and an ischaemic cuff, each titrated to ~7/10 pain. Both protocols showed impairment, but the cold test produced a stronger effect and correlated better with pain severity and disability on the FIQ. The inference: in a subset of patients the inhibitory system responds weakly or even “paradoxically”, fitting a central sensitisation model and potentially explaining chronic hyperalgesia.

This physiological profile is complemented by signs of neuroinflammation and altered transmitter balance. Reports describe reduced GABA-ergic activity and lower μ-opioid receptor availability in pain-modulating structures — another reason why merely “adding an analgesic” often fails in fibromyalgia. In effect, the pain system is tuned towards amplification rather than suppression.

Where trauma and the immune system fit in

Patients often ask: “What has trauma got to do with this?” Contemporary reviews note an association between fibromyalgia and PTSD/traumatic stress, with a tendency towards more severe symptomatology when PTSD is present. This does not mean trauma “causes” fibromyalgia in every case — but traumatic stress can heighten excitability of pain networks, disrupt sleep, and increase anxiety and depressive symptoms, thereby fuelling the pain cycle. A 2025 systematic review reports FM–PTSD links, including severity correlations, while emphasising data heterogeneity and the need for cautious interpretation.

There is also a bridge via the immune system. Neuroinflammation and possible systemic triggers are discussed in fibromyalgia, with reviews highlighting the role of gut dysbiosis and pro-inflammatory mediators that can reinforce central sensitisation. This stress–immune–pain loop matches the clinical picture of shallow sleep, marked fatigue and lowered pain thresholds.

Methodological nuance matters. Even with statistically different FIQ scores, both study groups remained within “severe impact” ranges — so clinical interpretation must be careful. Nonetheless, the CPM-impairment pattern aligns with meta-analytic evidence for defects in endogenous pain modulation in FM and helps explain the “the pain won’t budge although tests are normal” phenomenon.

Analgesics in fibromyalgia: where the limits lie

Hence the practical question — what to do about painkillers. Guidelines and reviews converge: classical analgesics have limited efficacy in fibromyalgia. NSAIDs and paracetamol are useful as adjuvants for co-existing nociceptive generators (e.g., osteoarthritis) but are weak for core FM pain. Opioids are generally not recommended given an unfavourable risk–benefit profile and lack of convincing efficacy, though tramadol — a weak opioid with serotonergic/noradrenergic actions — is sometimes considered in refractory cases.

As for agents with specific evidence in FM, three are FDA-approved in the USA — duloxetine, milnacipran and pregabalin. They are not “pure analgesics” but modulators of central pain processing. Effects are typically modest, with meaningful benefit for roughly 1 in 10 patients over 4–12 weeks. They are not magic bullets, but tools within a multidomain plan that includes patient education, sleep hygiene, graded activity and psychotherapeutic approaches. In Europe there are no EMA FM-specific approvals; many prescriptions are off-label.

EULAR guidance remains consistent: start with information and non-pharmacological measures; add medication as needed and symptom-targeted, avoiding routine opioids. Despite this, opioids continue to be used in some cohorts — an uneasy signal given long-term risks and lack of robust benefit.

• Fibromyalgia is not “joint inflammation to be dampened by NSAIDs” but a syndrome dominated by nociplastic pain and disordered modulation.
• Standard analgesics often yield weak or short-lived effects and are mainly for co-existing nociceptive sources.
• Centrally acting modulators can help a subset, but benefits are modest and should be time-limited and reviewed.
• Traumatic stress and PTSD are associated with more severe clinical pictures; attending to trauma is not “psychologising” but a realistic route to influence the pain loop via sleep, anxiety, hyperarousal and stress axes.

Implications for patients and clinics

CPM findings clarify why “one more painkiller” strategies often fail. It is more rational to build plans around restoring inhibitory balance: sleep and circadian routines, graded activity, trauma-informed psychotherapies, and self-regulation skills. Medicines are part of the toolkit, not the whole solution. This aligns with evidence of GABA-ergic changes and possible immune–microbiome contributions — where multiple nodes of dysregulation exist, a multicomponent response is needed.

Fibromyalgia is about the “volume” and filters of pain, not one inflamed joint. Psychological trauma can add decibels to that volume, the immune system can sustain the background noise, and analgesics may work only in fragments. The question is less “which drug next?” and more “how do we assemble a personal strategy that lowers system hyper-reactivity and restores controllability of pain?” Are we ready to shift from “suppress the pain” to “retune the system” — and what would be the first step in your case?